FDA Approves Apixaban for New Use

The U.S. Food and Drug Administration has approved a Supplemental New Drug Application for Bristol-Myers Squibb/Pfizer’s Eliquis (apixaban) as a preventative measure against potential pulmonary embolism-causing blood clots for patients who have undergone hip or knee replacement therapy, according to a news release.

Advertisement

Previously, Eliquis was only approved to reduce the risk of stroke and blood clots for patients with atrial fibrilliation not caused by a heart valve problem.

More Articles on FDA Approvals:

FDA Approves Migraine ‘Headband’ for Marketing
FDA Approves Myalept to Treat Lipodystrophy Complications
Medtronic Receives FDA 510(k) Clearance for Reveal LINQ Insertable Cardiac Monitor

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Rethinking Safety and Security in the Healthcare Environment

Thursday, July 23
1:00 PM - 2:00 PM CDT

Presenters: Jon Share, AxonDan Snyder, Advocate HealthKeith Hunter, Wellstar

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.